… the hypothesis that the BRAF V600E mutation is a prognostic indicator for PTC. The study
determined the prevalence of the BRAF V600E mutation in conventional PTC tissue samples …

… as a strong risk factor for aggressiveness and progression of PTC, even in conventionally
low-risk patients, use of BRAF mutation status may help to more appropriately target the TSH …

… In patients with conventional papillary thyroid cancer, BRAF V600E mutation was associated
with older age (P = 0.0381), lymph node metastasis (P = 0.0323), distant metastasis (P = …

… pattern in different structural components of the same tumor. … of cells with BRAF mutation in
the tumor from which more than … the solitary thyroid tumors32 and corroborate BRAF mutation …

… HTT, our data on BRAF mutation differ from those on … conventional PTC and HTT 16, 17. At
variance with their presence in 40% of cases of the oncocytic variant of PTC, BRAF mutations …

… The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with
conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2006;65: 364–8. …

… of BRAF mutation with one or more conventional high-risk clinicopathological characteristics
of PTC (40, 59, 61, 63, 64, 66, 67–69, 71, 72, 74, 76, 79, 80, 82, 83, 85). For example, in a …

… by a BRAF mutation (BRAF mut ), unified biomarkers for the genetically heterogeneous group
of BRAF wild type (BRAF wt … profiles between conventional BRAF wt and BRAF mut PTCs. …

… In this study, we evaluated the frequency of the BRAF mutation in conventional PTC of
Koreans and detected a higher frequency than the frequencies that had been reported in other …

… conventionally associated with a higher risk of thyroid cancer recurrence. There was no
significant association of BRAF mutation with patient age or gender or tumor multifocality. …